Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
BörsenkürzelGNFT
Name des UnternehmensGenfit SA
IPO-datumDec 19, 2006
CEOMr. Pascal Prigent
Anzahl der mitarbeiter180
WertpapierartOrdinary Share
GeschäftsjahresendeDec 19
AddresseParc Eurasante 885 avenue Eugene Avinee
StadtLOOS
BörseEuronext Paris
LandFrance
Postleitzahl59120
Telefon33320164000
Websitehttps://www.genfit.fr/
BörsenkürzelGNFT
IPO-datumDec 19, 2006
CEOMr. Pascal Prigent
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten